Literature DB >> 10793264

Cardiac electrophysiological effects of citalopram in guinea pig papillary muscle comparison with clomipramine.

P Pacher1, Z Bagi, Z Lakó-Futó, Z Ungvári, P P Nánási, V Kecskeméti.   

Abstract

The effect of citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, was studied on cardiac action potential configuration and compared with that of the tricyclic antidepressant (TCA) clomipramine. Conventional microelectrode techniques were used in right ventricular papillary muscle preparations of the guinea pig. Citalopram caused a concentration-dependent (10-100 microM) shortening of action potential duration (APD), depression of plateau and overshoot potential, and reduction of maximum velocity of depolarization (V(max)). No significant changes in resting membrane potential were observed. Similar results were obtained with clomipramine; however, reduction of V(max) and overshoot was more pronounced with clomipramine, whereas citalopram caused relatively greater shortening of APD. Effects of both drugs were partly reversible. The results indicate that the SSRI antidepressant citalopram, similarly to TCA compounds, alters cardiac action potential configuration in guinea pig ventricular muscle, probably owing to inhibition of cardiac Na(+) and Ca(2+) channels. Differences in cardiac side effects of the two drugs may be related to their different actions on cardiac action potential configuration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793264     DOI: 10.1016/s0306-3623(99)00048-8

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  4 in total

1.  Escitalopram block of hERG potassium channels.

Authors:  Yun Ju Chae; Ji Hyun Jeon; Hong Joon Lee; In-Beom Kim; Jin-Sung Choi; Ki-Wug Sung; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-09-18       Impact factor: 3.000

Review 2.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 3.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

Review 4.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.